Poles Gabriela C, Clark David E, Mayo Sara W, Beierle Elizabeth A, Goldfarb Melanie, Gow Kenneth W, Goldin Adam, Doski John J, Nuchtern Jed G, Vasudevan Sanjeev A, Langer Monica
Department of Surgery, Maine Medical Center, Portland, ME.
Department of Surgery, Division of Pediatric Surgery, University of Alabama at Birmingham, Children's of Alabama, Birmingham, AL.
J Pediatr Surg. 2016 Jul;51(7):1061-6. doi: 10.1016/j.jpedsurg.2015.11.005. Epub 2015 Dec 1.
Pediatric colorectal cancer (CRC) is rare. Comparison with adult CRC tumors, management, and outcomes may identify opportunities for improvement in pediatric CRC care.
CRC patients in the National Cancer Data Base from 1998 to 2011, were grouped into Pediatric (≤21years), early onset adult (22-50) and older adult (>50) patients. Groups were compared with χ(2) and survival analysis.
A total of 918 pediatric (Ped), 157,779 early onset adult (EA), and 1,304,085 older adults (OA) were identified (p<0.01 for all comparisons). Patients ≤50 presented more frequently with stage 3 and 4 disease (Ped: 62.0%, EA: 49.7%, OA: 37.3%) and rectal cancer (Ped: 23.6%, EA: 27.5%, OA: 19.2%). Pediatric histology was more likely signet ring, mucinous, and poorly differentiated. Initial treatment was usually surgery, but patients ≤50 were more likely to have radiation (Ped: 15.1%, EA: 18.6%, and OA: 9.2%) and chemotherapy (Ped: 42.0%, EA: 38.2%, and OA: 22.7%). Children and older adults showed poorer overall survival at 5years when compared to early onset adults. Adjusting for covariates, age ≤21 was a significant predictor of mortality for colon and rectal cancers (colon HR: 1.22, rectal HR: 1.69).
This is the largest cohort of pediatric CRC patients, revealing more aggressive tumor histology and behavior in children, particularly in rectal cancer. Despite standard oncologic treatment, age ≤21 was a significant predictor of mortality. This is likely owing to worse tumor biology rather than treatment disparities and may signal the need for different therapeutic strategies.
小儿结直肠癌(CRC)较为罕见。将其与成人CRC肿瘤、治疗及预后进行比较,可能会发现改善小儿CRC护理的机会。
1998年至2011年国家癌症数据库中的CRC患者被分为儿童组(≤21岁)、早发性成人组(22 - 50岁)和老年成人组(>50岁)。通过χ²检验和生存分析对各组进行比较。
共识别出918例儿童(Ped)、157,779例早发性成人(EA)和1,304,085例老年成人(OA)(所有比较p<0.01)。≤50岁的患者更常表现为3期和4期疾病(儿童组:62.0%,早发性成人组:49.7%,老年成人组:37.3%)以及直肠癌(儿童组:23.6%,早发性成人组:27.5%,老年成人组:19.2%)。儿童的组织学类型更可能为印戒细胞型、黏液型和低分化型。初始治疗通常为手术,但≤50岁的患者更可能接受放疗(儿童组:15.1%,早发性成人组:18.6%,老年成人组:9.2%)和化疗(儿童组:42.0%,早发性成人组:38.2%,老年成人组:22.7%)。与早发性成人相比,儿童和老年成人的5年总生存率较低。校正协变量后,年龄≤21岁是结肠癌和直肠癌死亡率的显著预测因素(结肠癌HR:1.22,直肠癌HR:1.69)。
这是最大规模的小儿CRC患者队列研究,揭示了儿童肿瘤组织学和行为更具侵袭性,尤其是直肠癌。尽管采用了标准的肿瘤治疗方法,但年龄≤21岁仍是死亡率的显著预测因素。这可能是由于肿瘤生物学特性较差而非治疗差异所致,可能表明需要不同的治疗策略。